Small brain metastases show similar one-year control with single- or multifraction radiosurgery
One-year local control was 96.1% with single-fraction SRS and 96.6% with fractionated SRS across 2,460 small brain metastases.
One-year local control was 96.1% with single-fraction SRS and 96.6% with fractionated SRS across 2,460 small brain metastases.
In 222 patients with gastrointestinal cancer and CNS metastases, median survival was 3.7 months, while prognostic-score discrepancies exceeded three months in 32–55%.
ROADS phase III found 1.3% versus 15.4% surgical bed recurrence at 12 months with cesium-131 tiles versus postoperative stereotactic RT.
In STEP, three-fraction preoperative stereotactic radiotherapy achieved 100% six-month local control and 7% one-year radiation necrosis in 63 patients.
Across 8,385 patients, reported radiation-related injury ranged from 6.8–30.4% in metastasis cohorts and 3.4–38.4% in AVMs, using noncomparable endpoints.
Among 879 SRS programs, 91% treated multiple lesions, while only 18.8% reported additional machine-specific QA for multi-lesion treatments.
Median survival was 11 versus 8 months with WBRT plus simultaneous boost, but nonrandomized treatment selection limits causal interpretation.
Only 22.6% of surveyed radiation oncologists routinely offered both hippocampal avoidance and memantine, while 46.8% offered neither as standard options.
A PTV-dependent V50% threshold flagged 10% of clinical SRS plans, with replanning reducing excess intermediate-dose exposure by a median 14%.
Fully automated Monaco planning met institutional WBRT constraints with similar overall plan quality, although optic nerve dose was higher than manually optimized plans.
Concurrent, deferred, or earlier cranial RT produced no significant survival difference in patients receiving pyrotinib for HER2-positive breast brain metastases.
Across 18 postoperative brain metastasis cavities, GammaTile generated consistent peak–valley heterogeneity, with the nominal 60 Gy prescription approximating D90.
A model using target volume and HyTEC limits estimated automated SRS prescription doses with approximately 1.3% mean absolute error.
Memantine preserved 6-month cognition versus placebo after radiotherapy for brain metastases, with benefits also seen in quality of life.
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.